Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.67 |
| ▸ | NPC1 | O15118 | 2/20 | 0.67 |
| ▸ | RAB9A | P51151 | 2/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.64 |
| ▸ | HTT | P42858 | 1/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.57 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 9/20 | 0.54 |
| ▸ | CYP2D6 | P10635 | 4/20 | 0.53 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.53 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.50 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.49 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933949 | 1.00 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL7399328 | 0.94 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL30401196 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL6480129 | 0.92 | SMN1; SMN2 (0.60) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL14514898 | 0.90 | SMN1; SMN2 (0.68) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL15140950 | 0.89 | SMN1; SMN2 (0.67) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL11990212 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL7277019 | 0.88 | SMN1; SMN2 (0.65) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL17946175 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19HTT | |
| SCHEMBL19876581 | 0.88 | SMN1; SMN2 (0.66) | SMN1; SMN2NPC1RAB9ACYP2C19HTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240002401-A1 | IMIDAZOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | GUANGZHOU HENOVCOM BIOSCIENCE CO., LTD. (CN) | 2024-01-04 | — | — | US | disclosed |
| CN-114507244-B | Imidazo thiazole compound, pharmaceutical composition and application thereof | 广州市恒诺康医药科技有限公司 | 2023-10-27 | — | — | CN | disclosed |
| EP-4242211-A1 | IMIDAZOTHIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | Guangzhou Henovcom Bioscience Co., Ltd. (CN) | 2023-09-13 | — | — | EP | disclosed |
| WO-2022100727-A1 | IMIDAZOTHIAZOLE COMPOUND, PHARMACEUTICAL COMPOSITION THEREOF, AND USE THEREOF | 广州市恒诺康医药科技有限公司 | 2022-05-19 | — | — | WO | disclosed |
| CN-114507244-A | Imidazothiazole compounds, pharmaceutical compositions thereof and uses thereof | 广州市恒诺康医药科技有限公司 | 2022-05-17 | — | — | CN | disclosed |
| EP-2688891-B1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | HOFFMANN LA ROCHE (CH) | 2017-11-15 | — | — | EP | disclosed |
| US-9090628-B2 | Benzoxazepin compounds selective for PI3K P110 delta and methods of use | GENENTECH, INC. (US) | 2015-07-28 | — | — | US | disclosed |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | GENENTECH, INC. (US) | 2012-09-27 | — | — | US | disclosed |
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | FANG JING (US) | 2012-03-29 | — | — | US | disclosed |
| US-8101634-B2 | Bicyclic compounds and use as antidiabetics | GLAXOSMITHKLINE LLC (US) | 2012-01-24 | — | — | US | disclosed |
| US-20050272751-A1 | 4-Substituted piperidine derivatives | BIOAXONE THERAPEUTIQUE INC. (CA) | 2005-12-08 | — | — | US | disclosed |
| WO-2005080394-A1 | 4-SUBSTITUTED PIPERIDINE DERIVATIVES | BIOAXONE THERAPEUTIQUE INC. (CA) | 2005-09-01 | — | — | WO | disclosed |
| US-5753659-A | ANTICOAGULANTS FOR BLOOD DISORDER, CARDIOVASCULAR DISORDER, THROMBOSIS, | ZENECA LIMITED (GB) | 1998-05-19 | — | — | US | disclosed |
| US-5750754-A | TERTIARY BUTYL 3-METHYL-4-SUBSTITUTED BUTYRATE; CHEMICAL INTERMEDIATES FOR ANTICAOGULANT DRUGS | ZENECA LIMITED (GB) | 1998-05-12 | — | — | US | disclosed |
| EP-0625509-B1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LTD (GB) | 1997-07-30 | — | — | EP | disclosed |
| US-5563141-A | INHIBIT CELL ADHESION FOR EXAMPLE, PLATELET AGGRE GATION | ZENECA LIMITED (GB) | 1996-10-08 | — | — | US | disclosed |
| US-5521199-A | TREATMENT OF ASTHMA | ZENECA LIMITED (GB) | 1996-05-28 | — | — | US | disclosed |
| EP-0690847-A1 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1996-01-10 | — | — | EP | disclosed |
| EP-0625509-A1 | N-alkyl substituted piperidine-derivatives with neurokinin receptor antagonist activity | ZENECA LIMITED (GB) | 1994-11-23 | — | — | EP | disclosed |
| WO-1994022835-A2 | HETEROCYCLIC COMPOUNDS AS PLATELET AGGREGATION INHIBITORS | ZENECA LIMITED (GB) | 1994-10-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120077812-A1 | BICYCLIC COMPOUNDS AND USE AS ANTIDIABETICS | GPR119, GOT2, PC | SMN1; SMN2 4188/4885NPC1 479/4885RAB9A 2962/4885 |
| US-20050272751-A1 | 4-Substituted piperidine derivatives | RHOC, PRPH, RHOT2 | SMN1; SMN2 51/4885NPC1 1941/4885RAB9A 81/4885 |
| US-20120245144-A1 | BENZOXAZEPIN COMPOUNDS SELECTIVE FOR PI3K P110 DELTA AND METHODS OF USE | PIK3CA, PIK3CD, PIK3R4 | SMN1; SMN2 3432/4885NPC1 2767/4885RAB9A 3359/4885 |
| US-20240002401-A1 | IMIDAZOTHIAZOLE COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND USES THEREOF | ENPP2, TPX2, UACA | SMN1; SMN2 697/4885NPC1 1940/4885RAB9A 1454/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.